Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Hanmi Pharmaceutical Senior Vice President Choi In-young, head of the R&D center, speaks to Korean media outlets at a press conference held in San Francisco, California, on Jan. 15. [LEE JAE-LIM] SAN ...

The Dow, S&P 500, and Nasdaq rally Wednesday as the stock market digests the latest CPI inflation report and earnings from several big U.S. banks.

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.